We identified genetic polymorphisms in the 5'-flanking region of the human cytochrome P450IIE1 gene and investigated the effect of these polymorphisms on the transcriptional regulation of the gene. PCR direct sequencing of the two homozygous alleles [types A (cl/ cl) and C (c2/c2)] revealed the existence of several point mutations in the distal 5'-flanking region of the gene, but no differences in the proximal promoter region. The DNA segment (-1372 to -960) placed upstream of SV40 promoter and the chloramphenicol acetyltransferase (CAT) gene enhanced the expression of the gene, and the enhancement of expression by type C DNA was about 10 times that by its type A counterpart. DNase I footprinting analysis showed at least one protected region in which one of the polymorphic loci (RsaI polymorphism) was located. The DNase I sensitivities and protection profiles of the two genotypes were different. The protected region had high homology to the consensus sequence of the binding region of liver specific transcription factor HNF1(LF-B1), and this was confirmed by gel retardation assay. These results indicate that genetic polymorphisms in the 5'-flanking region of the human P450IIE1 gene affect its binding of trans-acting factor and change its transcriptional regulation. This may lead to inter-individual differences of microsomal drug oxidation activity.
Cytochrome P450s are involved in the metabolisms of exogenous substances, including drugs and various chemical carcinogens, as well as endogenous substances (1) (2) (3) (4) . Cytochrome P450IIE 1 catalyzes the metabolic activation of the procarcinogen N-nitrosodimethylamine (5, 6 ) and cytotoxic carbon tetrachloride (7) . Nitrosoamines are potent carcinogens in many species of animals and are believed to be important in human carcinogenesis (3, 8) .
In the rat, expression of the P450IIE1 gene is developmentally regulated at the transcriptional level. The elevation of P450IIEl mRNA immediately after birth coincides with transcriptional activation (9, 10) . Post-transcriptional regulation of this P450 also participates in control of the level of this enzyme. Administration of inducers such as acetone, pyrazole, and ethanol to rats caused induction of P450IIE1 without affecting its mRNA level (9) . Mechanisms for stabilizing the mRNA and protein levels in the rat have been reported (11) , but little is known about the regulation of this P450 in humans.
The activities for metabolizing drugs and carcinogens are known to be genetically variable in human individuals (3, 12) . We have reported a good correlation between increased risk of lung cancer and genetic polymorphisms of P4501A1, which is involved in metabolic activation of benzo
[ a] pyrene (13, 14) . This observation suggests that genetic variation in other forms of P450 may also be responsible for individual differences in susceptibility to human chemical carcinogenesis. Variation in activity to metabolize N-nitrosodialkylamines was observed in liver microsomes from different individuals (15) , and Wrighton et al. (16) reported that the amounts of protein and mRNA of P450IIE1 differed in individual human livers. These observations suggest that the inter-individual variation in metabolic activity can be ascribed to some differences in transcriptional regulation. Recently, we found PstI and RsaI polymorphisms in complete linkage disequilibrium in the 5'-flanking region of the human P450IIE1 gene (17) . Namely, the gene frequencies of cl (PstI site -, RsaI site +) and c2 (PstI site +, Rsal site -) were 0.807 and 0.193 in 202 unrelated Japanese. Since P450IIE1 has been identified as a single gene in humans (18) , genetic polymorphisms of this gene, especially in its regulatory region, may be responsible for this variation.
In this study, we analyzed the structures of the cl and c2 genes, and identified the mutations in the 5'-flanking region. We found a marked difference between the transcriptional activation activities of the two types. We further identified the cis-acting element and trans-acting factor HNF1, which may be responsible for the difference in expression of the P450IIEl gene in different individuals. Genomic DNA and Oligonucleotide-Blood samples were obtained from individuals of genotypes A, B, and C, and DNA was isolated from the peripheral lymphocytes. Samples of DNA (1 pg) were added to the PCR mixture, and the products were used as templates for direct sequencing and DNase I footprinting. Oligonucleotides were synthesized in an Applied Biosystems Model 381 DNA synthesizer.
MATERIALS AND METHODS

Materials
Detections of Rsal and Pstl Polymorphisms-The genotypes of the P450IIE1 gene ascribed to the RsaI and Pstl sites in the 5'-flanking region were identified as RFLPs by PCR. PCR was performed by 25 thermal cycles under the following conditions: 1 min at 95'C for denaturation, 1 min at 55'C for primer annealing, and 1 min at 72'C for primer extension. The PCR-amplified DNA fragments (J9-J8) including the polymorphic site were digested with RsaI or PstI, and subjected to electrophoresis in 1.8% agarose gel.
Direct DNA Sequencing of PCR Amplified DNA-PCRdirect sequencing was performed from -1372 to the beginning of the first exon (+ 72). Single-stranded 21 mer nucleotides were used as primers in the PCR (J9-J8, J19-J14, J15-J16), and samples of 200 ng of purified products together with 4 pmol of the synthesized 21 mer primers (J8-24) were used for sequencing by the dideoxy method with a Sequenase sequencing kit.
Plasmid Construction, DNA Transfection, and CAT Assays-The DNA segments (-1372 to -960) amplified by PCR from types A and C DNA were subcloned into the blunted XbaI site of pCAT-Promoter plasmid. The subcloned DNAs were sequenced and their sequences were confirmed to be completely consistent with the results of PCR-direct sequencing. Transient transfections into HepG2 cells were performed by the calcium phosphate-DNA precipitation method (19) . Cellular extracts from transfected cells were prepared and assayed for CAT enzyme activity (20) . The activities were evaluated by autoradiography with a Fuji Bio-Image Analyzer BAS 2000 (Fuji film, Tokyo).
PCR-DNase I Footprint Analysis-Labeled DNA fragments of the P450IIE1 gene for footprint analysis were produced by the PCR method. One primer was kinated with T4 polynucleotide kinase in the presence of [y-32P]ATP.
The reaction mixture (50 pl) for footprinting contained 5 pl of 10 x binding buffer [ 100 mM Tris-HCl (pH 7.5), 500 mM sodium chloride, 10 mM dithiothreitol, 5 mM EDTA, 25 mM magnesium chloride, 50% glycerol], 2 pg of poly-(dI-dC), 20 fmol of the labeled PCR product, and 5 to 50 pg of nuclear extract protein prepared from rat liver as described by Gorski et al. (21) . The mixture was incubated on ice for 30 min, and then mixed with an equal volume of 1 x binding buffer. The mixture was preincubated at 25'C for 1 min, and then 2 pl of DNase I solution (50 units/ml in 5 mM calcium chloride and 10 mM magnesium chloride) was added. Partial digestion of the DNA fragments was carried out at 25'C for 1 min, and the reaction was terminated by adding 25 p 1 of stop solution [ 1.5 M sodium acetate (pH 5.2), 20 mM EDTA, and 100 pg/ml tRNA]. The partially digested DNA was recovered by phenol extraction and ethanol precipitation. The pelleted DNA was dissolved in formamide dye and analyzed by polyacrylamide gel electrophoresis. The labeled PCR products were used for a base-specific cleavage reaction by the method of Maxam and Gilbert (22) as a control.
Gel Retardation Analysis-The double-stranded 32 mer nucleotides dRsaA (5'-gatcTTCATTGTTAATATAAAAG-TACAAAATT-3' / 3' -AAGTAACAATTATATTTTCATGTTTTAActag-5') and dRsaC (5'-gatcTTCATTGTTAATA-TAAAAGTATAAAATT-3' / 3' -AAGTAACAATTATATTTTCATATTTTAActag-5') were used as probes. Four nucleotides, gatc, were added to the 5' end of the synthetic nucleotides for the labeling reaction with Klenow fragment and [a-32P]dCTP. A labeled probe of about 10 fmol and 5 pg protein of nuclear extract were added to the reaction mixture. Other conditions were the same as for footprint analysis. The samples were loaded onto native polyacrylamide gel and electrophoresis was carried out in 0.25 x TBE at 180 V.
The cold double-stranded 30 mer nucleotides dHNF1 (5'-TTAATTTGGTTAGTAATTACTAAACACTGA-3'/ 3'-AATTAAACCAATCATTAATGATTTGTGACT-5'), which code the HNF1 binding site of the human albumin gene (23) , and the 26 mer nucleotides dXRE (5'-CCTCCA-GGCTCTTCTCACGCAACTCC-3'/3'-GGAGGTCCGAG-AAGAGTGCGTTGAGG-5') which code the XRE region (24) of the rat P450IA1 gene, were added to the mixture as specific and unspecific competitors, respectively.
RESULTS
Identification of Polymorphic Mutation in the 5'-Flanking Region of P450IIE1-The nucleotide sequence of the 5'-flanking region of the human P450IIE1 gene was determined by Umeno et al. (18) . As previously reported (17) we found genetic polymorphisms originating from two different loci in the 5'-flanking region of the gene by RFLPs in Southern blotting. These two polymorphisms were completely linked with each other. The predominant Fig. 1 . RFLPs of PCR-amplified fragments obtained with Rsal and Pstl. The primers indicated as J8 and J9 in Fig. 3 were used for PCR amplification. The PCR products from type A, B, and C DNA were digested with PstI or Psal, and subjected to agarose gel electrophoresis. Lanes A, B, and C are types A (c1/cl), B (c1/ c2), and C (c2/c2), respectively. homozygous allele, the heterozygous allele, and the homozygous rare allele were named type A (cl/c1), type B (c1/ c2), and type C (c2/c2), respectively. In this study, this finding was confirmed by digestion of the DNA fragments amplified by PCR (Fig. 1) with the primers J8-J9 (shown in Fig. 3 ). On Pstl-digestion of the fragments amplified from type A DNA, only a single undigested band was observed at 410 bp; the fragments from type C DNA gave bands of digestion products at 290 and 120 bp; type B gave three bands at 410, 290, and 120 bp. On digestion with RsaI, the fragments from type A gave bands at 360 and 50 bp; type C gave a single band at 410 bp; type B gave all three bands.
We then analyzed these individual genotypes by PCR direct sequencing. As shown in Fig. 2 , type A DNA had GTGCAG at position -1259, while type C had CTGCAG at the same position, forming a Pstl site. On the other hand, type A DNA had an RsaI site as GTAC as position -1019, while type C DNA had GTAT at the same position. These results were consistent with our previous observations (17) .
As shown in Fig. 3 , we found other point mutations at -1165 , -991, and -771 but no differences between -770 and the transcriptional start site. Namely, the promoter region which includes the TATA box, BTE (basic transcription element) (25) , and HNF1 consensus region was identical in types A and C.
Transcriptional Enhancement by the DNA Segment Including Polymorphic Sites-To investigate the effect of genetic polymorphisms in the distal 5'-flanking region on transcriptional regulation of the P450IIE1 gene, we carried out a CAT analysis (Fig. 4) . The DNA fragments (-1372 to -960) amplified by the PCR from type A and C DNAs were placed upstream of the SV40 promoter and CAT gene, and were transfected into the human hepatoma cell line HepG2, which expresses the albumin gene (26) . The positive control, pCAT-Control plasmid, which contains the SV40 promoter-enhancer sequences inserted upstream of the CAT gene, is expressed at a high level in the HepG2 cells (lane 1), and its activity was used as a standard and taken to be 100%. The polymorphic region of the P450IIE1 The experiments were independently repeated three times, and all the results showed high activity of type C. Furthermore, to examine possible influences of DNA preparation, the plasmids were prepared again from other colonies on the plates; the same results were obtained. These results indicate that the polymorphic mutations in the distal 5'-flanking region of the P450IIE1 gene affect the expression level of the CAT gene, and that these polymorphic mutations cause marked difference in its transcriptional activity. DNase I Footprint Analysis Using DNA Amplified by PCR-To determine the cis-acting elements between -1372 and -960 , responsible for the difference in CAT activities in the two genotypes, we carried out footprint analysis using DNA fragments amplified by the PCR with a rat liver nuclear extract. Figure 5 shows that the profiles of type A and C DNAs in the DNase I digests were the same except in the region around the point mutation at -1017 (RsaI polymorphic locus) (Fig. 5, lane 1) , possibly due to some conformational differences in this region. In both genotypes, protection against DNase I digestion was clearly observed at about -1030; however, the protected area in type A DNA was more extensive than that in type C DNA. These observations indicate that a nuclear factor binds to this area, although the binding profiles of type A and C DNAs were different.
The protected region (Fig. 6A ) was highly homologous to the consensus sequence of the binding region of the liver specific transcription factor HNF1 (LF-Bl) (31) . The sequence of this protected region showed high homology with that of the rat P450IIE1 gene (Fig. 6B) . This region included a polymorphic point mutation (C to T).
'Gel Retardation Analysis -Gel retardation assay of the two types of DNA was carried out with rat liver nuclear extract, using oligonucleotides that encode the protected area to determine whether HNF1 actually bound to this region. Some proteins reacted with these DNA fragments (Fig. 7A) , and the formation of the complex of type A and C DNA was inhibited by the presence of large amounts of unlabeled type A and C oligonucleotides, respectively. Furthermore, the inhibition of bindings to type A and C DNAs was observed even in the presence of excess amounts of type C and A oligonucleotides, respectively. These observations suggest that these bindings are specific to the DNA sequences and that a common factor forms a complex with type A and C oligonucleotides. The effect of oligonucleotides (dHNF1) encoding the HNF1 binding sequence of the human albumin gene (27) was investigated by gel retardation analysis. The formation of complexes of both type A and C DNAs was completely inhibited by an excess amount of dHNF1, but not of the xenobiotic response element (dXRE) (Fig. 7B ). These observations showed that a liver-specific transcription factor, HNF1 (LF-B1), in the nuclear extract bound to both types of DNA including the polymorphic Rsal site.
DISCUSSION
The object of our study is to elucidate the molecular mechanisms of genetically determined differences among individuals in drug oxidation activity of microsomes. As cytochrome P450 plays an important role in this system, we focused our attention on the relation between genetic polymorphism of P450 and individual susceptibility to drugs. Polymorphisms in the coding region of P450s can cause amino acid substitution and hence affect substrate specificity. A typical example of this type has already been observed in P450IID (32) (33) (34) , which participates in debrisoquine metabolism. On the other hand, when polymorphic loci exist in the regulatory region of P450 gene, the difference can be explained by change in the expression level of P450 mRNA. This type of polymorphism has not yet been reported for P450s. Judging from the observed variation in mRNA contents of P45011E1 in different individuals (16) , the inter-individual difference in the activity of N-nitrosodimethylamine demethylase (15) was expected to be due to structural changes in the regulatory region of the gene.
In this paper, we showed that genetic polymorphisms in the 5'-flanking region of the human P4501IE1 gene caused marked differences in its transcriptional activity. When the DNA segment from -1372 to -960 was amplified by PCR and fused to a reporter gene with the SV40 promoter, the enhancer activity for type C DNA was about 10 times that of type A DNA. In this region, five differences in nucleotides in the two genotypes have been observed at -1259 (Pstl polymorphism) , -1165, -1019 (RsaI polymorphism), -991, and -771. From DNase I footprint analysis we concluded that the polymorphic Rsal site (-1019) was essential for the marked difference in the transcriptional activities.
We also demonstrated the participation of liver specific transcription factor HNF1 in regulation of the gene. Recently, many cis-acting elements in the 5'-flanking regions of liver-specific genes have been identified, and transcriptional activator proteins such as HNF1 (35, 36) , C/EBP (37, 38) , DBP (39), LAP (40), HNF3, and HNF4 (41) have been found to control the liver-specific expressions. One of these factors, HNF1, was found to be a regulator of liver specific expression, and a common sequence motif that can form a binding complex with this protein factor has been found in the genes of albumin (23, 42) , a-, and /3-fibrinogen (28), a-antitrypsin (27, 28), a -fetoprotein (43, 44) , transthyretin (45) , aldolase B (46), pyruvate kinase (30, 47) , and hepatitis B virus large surface protein (29, 48) . Like these proteins, P450IIE1 is expressed predominantly in liver cells (49) . So the protected area, including the polymorphic locus detected by footprint analysis should be important for its predominant expression in liver. Very recently, Ueno and Gonzalez reported on the transcriptional regulation of the rat P450-IIE1 gene (50) . They showed the existence of three protected regions in the promoter region by DNase I footprint analysis. The region between -127 and -89, which is operationally equivalent to the binding site for HNF1, was responsible for 90% of the in vitro transcription activity in adult rat liver. There is a consensus sequence for the binding site of HNF1 in the promoter region of the human P450IIE1 gene (Fig. 3) , but we could not find any sequence difference in this promoter region in the two human genotypes. We therefore concluded that the interindividual difference in transcriptional regulation was ascribable to genetic polymorphisms in a more distal regulatory region. As the HNF1 binding site has been shown to function in both an enhancer and a promoter region in the human albumin gene (51), we are now examining the interaction between these two elements in the P450IIE1 gene.
A single base change from G (type A) to C (type C) at -1019 altered the protection profiles against DNase I digestion and resulted in marked change in the transcriptional activation activity. However, we could not detect any quantitative difference in DNA-protein complex formation in the two genotypes. This finding is interesting because it suggests that DNA-protein complex formation, although necessary, may not be sufficient for transcriptional activation. Hollenberg and Evans (52) reported that a single mutation of the human glucocorticoid receptor, which converts the lysine directly following the first zinc 
